IP Library › Granted Patent US 9,815,877
Granted Patent B2
US 9,815,877 · App. 14/405,932 · Granted Nov 14, 2017

Controlled gene expression methods

Inventors: Gerd Blobel (Bala Cynwyd, PA); Wulan Deng (Philadelphia, PA)
Assignee: The Children's Hospital of Philadelphia
C07K14/4702A61K48/00C07K14/47C12N15/63C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,877
App. No.
14/405,932
Granted
Nov 14, 2017
Kind
B2
Abstract

Methods and compositions for controlling gene expression are disclosed.

Claims (19)

1. A nucleic acid molecule encoding a polypeptide comprising a DNA binding domain and a looping factor, wherein said looping factor is a fragment of LIM domain binding 1 (Ldb1), wherein said fragment of Ldb1 comprises an amino acid sequence that has at least 90% identity with amino acids 1 to 200 of SEQ ID NO: 1.

2. The nucleic acid molecule of claim 1 , wherein said DNA binding domain and said looping factor are linked through a covalent bond or an amino acid linker.

3. The nucleic acid molecule of claim 1 , wherein said Ldb1 is human.

4. The nucleic acid molecule of claim 1 , wherein said fragment of Ldb1 comprises amino acids 1 to 200 of SEQ ID NO: 1.

5. The nucleic acid molecule of claim 1 , wherein said DNA binding domain comprises a zinc finger protein or a transcription activator-like effector protein.

6. The nucleic acid molecule of claim 1 , wherein said DNA binding domain specifically binds a target sequence in the promoter of a gene of interest.

7. The nucleic acid molecule of claim 6 , wherein said promoter is a globin promoter.

8. The polypeptide encoded the nucleic acid molecule of claim 1 .

9. A vector comprising the nucleic acid molecule of claim 1 .

10. A composition comprising at least one polypeptide of claim 8 and at least one pharmaceutically acceptable carrier.

11. A composition comprising at least one nucleic acid molecule of claim 1 and at least one pharmaceutically acceptable carrier.

12. A method of modulating the expression of a gene of interest in a cell, said method comprising expressing the nucleic acid molecule of claim 1 in the cell.

13. The method of claim 12 , wherein said method comprises expressing a first and second nucleic acid molecule in the cell,

wherein said first nucleic acid molecule encodes a first polypeptide comprising a first DNA binding domain and a first looping factor, wherein said first looping factor is a fragment of LIM domain binding 1 (Ldb1), and wherein said first DNA binding domain specifically binds to a target sequence in the promoter of said gene of interest, and

wherein said second nucleic acid molecule encodes a second polypeptide comprising a second DNA binding domain and a second looping factor, wherein said second looping factor is a fragment of LIM domain binding 1 (Ldb1), and wherein said second DNA binding domain specifically binds to a target sequence in the locus control region of said gene of interest.

14. The method of claim 13 , wherein said fragment of Ldb1 comprises amino acids 1 to 200 of SEQ ID NO: 1.

15. The nucleic acid molecule of claim 7 , wherein said promoter is the fetal gamma globin promoter.

16. The nucleic acid molecule of claim 1 , wherein said looping factor consists of amino acids 1 to 200 of SEQ ID NO: 1.

17. The nucleic acid molecule of claim 1 , wherein said fragment of Ldb1 comprises an amino acid sequence that has at least 97% identity with amino acids 1 to 200 of SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2017
From: BLOBEL, GERD; DENG, WULAN
To: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 043802/0783 →
Continuity (2)
Provisional Application 61656961 · Jun 7, 2012
Related Publication 20150152151A1 · Jun 4, 2015